BridgeMD
New treatment option for Tobacco Use Disorder
Official title TUBSIS 2.0 - Tobacco Use Behavioral Support and Intervention System
ClinicalTrials.gov ID: NCT07568483
What this study is testing
- What it's testing
- Background: Tobacco smoking and vaping remains public health concern, with many adults continuing to experience difficulties accessing appropriate support for smoking cessation in Switzerland and Türkiye. Structural barriers, including stigma related to attempting to quit, limited financial and time resources, low awareness of the health risks associated with tobacco smoking- and vaping-reduce engagement with traditional services.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age: 18 years or older
- Smoking status: Smoked on ≥1 day in the past 30 days, and/or Smoked at least 100 cigarettes in lifetime
- Internet access: Stable internet connection and access to a smartphone, tablet, or computer during interaction of the TUBSIS 2.0 web-based platform.
- Language: Sufficient reading and listening comprehension in the study language (German, English or Turkish)
- Contact: Valid email address and phone number (optional) for study communication, reminders and incentive payments
You likely can't join if
- Individuals who do not meet the inclusion criteria are excluded.
See the full eligibility criteria
- Age: 18 years or older
- Smoking status: Smoked on ≥1 day in the past 30 days, and/or Smoked at least 100 cigarettes in lifetime
- Internet access: Stable internet connection and access to a smartphone, tablet, or computer during interaction of the TUBSIS 2.0 web-based platform.
- Language: Sufficient reading and listening comprehension in the study language (German, English or Turkish)
- Contact: Valid email address and phone number (optional) for study communication, reminders and incentive payments
- Consent: Provided electronic informed consent on TUBSIS 2.0 web-based platform which is developed and administrated by ISGF.
- Study procedures: Agreement to randomization (intervention or control) and completion of study assessments at four time points (baseline, mid-intervention, post-intervention and 8-week follow-up)
- Individuals who do not meet the inclusion criteria are excluded.
The study team makes the final eligibility decision.
Where it's taking place
- Zurich, Switzerland
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zurich, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.